Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
TORRENT PHARMA ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
TORRENT PHARMA Mar-23 |
ADCOCK INGRAM Jun-14 |
TORRENT PHARMA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,723 | 316 | - | |
Low | Rs | 1,243 | 228 | - | |
Sales per share (Unadj.) | Rs | 284.2 | 94.0 | - | |
Earnings per share (Unadj.) | Rs | 36.8 | -23.7 | - | |
Cash flow per share (Unadj.) | Rs | 57.7 | -19.6 | - | |
Dividends per share (Unadj.) | Rs | 22.00 | 0 | - | |
Avg Dividend yield | % | 1.5 | 0 | - | |
Book value per share (Unadj.) | Rs | 183.1 | 73.8 | - | |
Shares outstanding (eoy) | m | 338.45 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 5.2 | 2.9 | 180.3% | |
Avg P/E ratio | x | 40.3 | -11.5 | -350.9% | |
P/CF ratio (eoy) | x | 25.7 | -13.9 | -185.5% | |
Price / Book Value ratio | x | 8.1 | 3.7 | 219.6% | |
Dividend payout | % | 59.8 | 0 | - | |
Avg Mkt Cap | Rs m | 501,779 | 45,919 | 1,092.7% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 16,777 | 2,882 | 582.1% | |
Avg. sales/employee | Rs Th | 0 | 3,696.8 | - | |
Avg. wages/employee | Rs Th | 0 | 671.3 | - | |
Avg. net profit/employee | Rs Th | 0 | -931.5 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 96,202 | 15,870 | 606.2% | |
Other income | Rs m | 632 | 111 | 568.9% | |
Total revenues | Rs m | 96,834 | 15,982 | 605.9% | |
Gross profit | Rs m | 28,240 | -2,750 | -1,026.8% | |
Depreciation | Rs m | 7,066 | 685 | 1,031.6% | |
Interest | Rs m | 3,334 | 430 | 775.6% | |
Profit before tax | Rs m | 18,472 | -3,754 | -492.1% | |
Minority Interest | Rs m | 0 | -10 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 6,019 | 235 | 2,566.1% | |
Profit after tax | Rs m | 12,452 | -3,999 | -311.4% | |
Gross profit margin | % | 29.4 | -17.3 | -169.4% | |
Effective tax rate | % | 32.6 | -6.2 | -521.5% | |
Net profit margin | % | 12.9 | -25.2 | -51.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 53,137 | 11,624 | 457.1% | |
Current liabilities | Rs m | 54,473 | 6,540 | 832.9% | |
Net working cap to sales | % | -1.4 | 32.0 | -4.3% | |
Current ratio | x | 1.0 | 1.8 | 54.9% | |
Inventory Days | Days | 15 | 111 | 14.0% | |
Debtors Days | Days | 7 | 124 | 6.0% | |
Net fixed assets | Rs m | 91,390 | 6,775 | 1,348.8% | |
Share capital | Rs m | 1,692 | 74 | 2,296.7% | |
Net worth | Rs m | 61,981 | 12,457 | 497.6% | |
Long term debt | Rs m | 24,962 | 4,377 | 570.2% | |
Total assets | Rs m | 144,682 | 23,531 | 614.8% | |
Interest coverage | x | 6.5 | -7.7 | -84.6% | |
Debt to equity ratio | x | 0.4 | 0.4 | 114.6% | |
Sales to assets ratio | x | 0.7 | 0.7 | 98.6% | |
Return on assets | % | 10.9 | -15.2 | -71.9% | |
Return on equity | % | 20.1 | -32.1 | -62.6% | |
Return on capital | % | 25.1 | -19.8 | -126.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 23,681 | 1,355 | 1,748.1% | |
From Investments | Rs m | -24,153 | -416 | 5,806.8% | |
From Financial Activity | Rs m | 774 | 3,973 | 19.5% | |
Net Cashflow | Rs m | 1,101 | 4,912 | 22.4% |
Compare TORRENT PHARMA With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare TORRENT PHARMA With: SANJIVANI PA NATCO PHARMA IND. SWIFT WANBURY UNICHEM LAB
After opening the day on high, Indian share markets continued the momentum as the session progressed and ended the higher.